SeekingAlpha · Oct 26, 2026
Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
Bolt Biotherapeutics, Inc. (BOLT) M&A Call October 26, 2026 8:30 AM EDTCompany ParticipantsWilliam Quinn - CEO, CFO, President, Secretary &...
NASDAQ · BOLT
Bolt Biotherapeutics, Inc.
Healthcare · Biotechnology
$6.57
Down-$0.03 (-0.46%)
Updated Nov 4, 2026, 11:49 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 10.99M
- P/E ratio
- -0.26
- Dividend yield
- 0.00%
- 52-week range
- $3.10 – $7.78
- Volume
- 51.39K
- Avg. volume
- 40.59K
Price performance · BOLT
BOLT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BOLT closed at $6.57 after 21 trading sessions, up 87.18% for the selected period.
- Last close
- $6.57
- Period change
- +87.18%
- Period low
- $3.51
- Period high
- $6.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $6.32 | $6.74 | $6.10 | $6.57 | 51.39K |
| Nov 2, 2026 | $6.58 | $6.58 | $6.18 | $6.24 | 50.4K |
| Oct 30, 2026 | $6.28 | $6.59 | $6.09 | $6.59 | 249.91K |
| Oct 29, 2026 | $6.47 | $6.61 | $6.30 | $6.36 | 76.27K |
| Oct 28, 2026 | $6.34 | $6.60 | $6.28 | $6.58 | 82.98K |
| Oct 27, 2026 | $6.58 | $6.64 | $6.22 | $6.37 | 177.8K |
| Oct 26, 2026 | $6.66 | $6.865 | $6.2001 | $6.59 | 423.7K |
| Oct 23, 2026 | $6.98 | $7.78 | $5.99 | $6.27 | 12.88M |
| Oct 22, 2026 | $4.06 | $4.2099 | $4.0257 | $4.19 | 14.05K |
| Oct 21, 2026 | $4.33 | $4.4801 | $4.05 | $4.14 | 34.47K |
| Oct 20, 2026 | $4.05 | $4.33 | $4.05 | $4.31 | 29.27K |
| Oct 19, 2026 | $3.9467 | $4.20 | $3.9467 | $4.04 | 21.94K |
| Oct 16, 2026 | $4.46 | $4.48 | $3.955 | $4.00 | 10.12K |
| Oct 15, 2026 | $4.14 | $4.44 | $3.85 | $4.24 | 9.26K |
| Oct 14, 2026 | $4.28 | $4.375 | $3.76 | $3.98 | 31.07K |
| Oct 13, 2026 | $4.26 | $4.385 | $4.25 | $4.285 | 12.83K |
| Oct 12, 2026 | $4.13 | $4.678 | $4.13 | $4.24 | 28.73K |
| Oct 9, 2026 | $3.77 | $4.40 | $3.77 | $4.11 | 87.22K |
| Oct 8, 2026 | $3.545 | $3.65 | $3.4474 | $3.65 | 10.48K |
| Oct 7, 2026 | $3.65 | $3.79 | $3.381 | $3.60 | 54K |
| Oct 6, 2026 | $3.4529 | $3.639 | $3.4529 | $3.51 | 23.26K |
Latest BOLT news
The latest Smart Investors Daily articles mentioning BOLT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BOLT research
Overview
Company profile and research snapshot.
Company profile
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 29, 2026 | Rodman & Renshaw | Buy | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | Lake Street | Buy | — |
| May 20, 2025 | Lake Street | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platformPRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, with a Phase 2 study in EoE planned; patient data from all four trials expected beginning in the second quarter of 2027Concurrent private placement of $120 million in upfront financing with the potential to
Benzinga · Oct 23, 2026
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics (NASDAQ:LUCD)
Benzinga · Oct 23, 2026
Bolt’s Acquisition Positions It To Advance Prana’s Inspire Multispecific Antibody Pipeline; Phase 2 PRA-216 Readouts Expected Starting Q2 2027
Prana’s Pipeline Overview and Development MilestonesPrana’s focus is to develop the next generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. The lead program,
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
